Tumor Biology

, Volume 36, Issue 4, pp 2241–2248 | Cite as

Clinicopathologic characteristics and molecular subtypes of microinvasive carcinoma of the breast

  • Li Wang
  • Wei Zhang
  • Shuhua Lyu
  • Xia Liu
  • Tongxian Zhang
  • Shan Liu
  • Ying Qin
  • Xiaoqi Tian
  • Yun Niu
Research Article


Patients with microinvasive carcinoma often have favorable prognosis, but it remains unclear whether this special type of breast cancer represents a distinct morphological entity with its own biological features and clinical behavior distinct from those of ductal carcinoma in situ (DCIS). The study is a retrospective analysis of a large patient cohort from a single institution. One hundred and thirty one microinvasive carcinoma and 451 DCIS cases were collected. ER, PR, HER2, and Ki67 were examined by immunohistochemistry in pathological sections. We assessed the clinicopathologic characteristics, molecular features, and survival status of microinvasive carcinoma and compared to those of DCIS. Microinvasive carcinoma differed from DCIS with respect to tumor size, lymph node status, and initial presentation (P < 0.05). There was a significant difference in nuclear grade among microinvasive carcinoma of different molecular subtype (P < 0.05). The clinicalpathologic features and outcomes of patients with microinvasive carcinoma were similar to those with DCIS. The 5-year OS rate for microinvasive carcinoma and DCIS patients was 99.0 and 99.2 %, respectively. A combination of pathologic, clinical, and molecular factors may ultimately reveal more powerful and robust measures for disease classification than any one modality alone. Microinvasive carcinoma does not significantly predict for worse DFS or OS in comparison with patients with DCIS.


Breast cancer Microinvasive carcinoma Pathological features Molecular subtypes Prognosis 



This work was supported by National Science Foundation of China (81470119; 81172532).

Conflicts of interest



  1. 1.
    Siegel R, Ma J, Zou Z, Jemal A. Cancer statistics, 2014. CA Cancer J Clin. 2014;64:9–29.CrossRefPubMedGoogle Scholar
  2. 2.
    Fan L, Zheng Y, Yu KD, Liu GY, Wu J, Lu JS, et al. Breast cancer in a transitional society over 18 years: Trends and present status in Shanghai, China. Breast Cancer Res Treat. 2009;117:409–16.CrossRefPubMedGoogle Scholar
  3. 3.
    de Mascarel I, MacGrogan G, Mathoulin Pélissier S, Soubeyran I, Picot V, Coindre JM. Breast ductal carcinoma in situ with microinvasion. Cancer. 2002;94:2134–42.CrossRefPubMedGoogle Scholar
  4. 4.
    Yu KD, Wu LM, Liu GY, Wu J, Di GH, Shen ZZ, et al. Different distribution of breast cancer subtypes in breast ductal carcinoma in situ (DCIS), DCIS with microinvasion, and DCIS with invasion component. Ann Surg Oncol. 2011;18:1342–8.CrossRefPubMedGoogle Scholar
  5. 5.
    Vieira CC, Mercado CL, Cangiarella JF, Moy L, Toth HK, Guth AA. Microinvasive ductal carcinoma in situ: Clinical presentation, imaging features, pathologic findings, and outcome. Eur J Radiol. 2010;73:102–7.CrossRefPubMedGoogle Scholar
  6. 6.
    Silver SA, Tavassoli FA. Mammary ductal carcinoma in situ with microinvasion. Cancer. 1998;82:2382–90.CrossRefPubMedGoogle Scholar
  7. 7.
    Lagios MD, Westdahl PR, Margolin FR, Rose MR. Duct carcinoma in situ. Relationship of extent of noninvasive disease to the frequency of occult invasion, multicentricity, lymph node metastases, and short‐term treatment failures. Cancer. 1982;50:1309–14.CrossRefPubMedGoogle Scholar
  8. 8.
    Ellis IO, Tavassoli FA. Microinvasive carcinoma. In: Tavassoli FA, Devilee P, editors. Pathology & genetics: Tumours of the breast and female genital organs. 3rd ed. Lyon: IARC Press; 2003. p. 74–5.Google Scholar
  9. 9.
    Edge SB, Compton CC. The American Joint Committee on Cancer: the 7th edition of the AJCC cancer staging manual and the future of TNM. Ann Surg Oncol. 2010;17:1471–4.CrossRefPubMedGoogle Scholar
  10. 10.
    Pinder SE, Ellis IO, Schnitt SJ, Tan PH, Rutgers E, Morrow M. Microinvasive carcinoma. In: Lakhani SR, Ellis IO, Schnitt SJ, editors. WHO classification of tumours of the breast. 4th ed. Lyon: IARC Press; 2012. p. 96–7.Google Scholar
  11. 11.
    Clark S, Warwick J, Carpenter R, Bowen R, Duffy S, Jones J. Molecular subtyping of DCIS: Heterogeneity of breast cancer reflected in pre-invasive disease. Br J Cancer. 2011;104:120–7.CrossRefPubMedGoogle Scholar
  12. 12.
    Goldhirsch A, Winer EP, Coates AS, Gelber RD, Piccart-Gebhart M, Thürlimann B. Personalizing the treatment of women with early breast cancer: Highlights of the St Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2013. Ann Oncol. 2013;24:2206–23.CrossRefPubMedPubMedCentralGoogle Scholar
  13. 13.
    Virnig BA, Tuttle TM, Shamliyan T, Kane RL. Ductal carcinoma in situ of the breast: a systematic review of incidence, treatment, and outcomes. J Natl Cancer Inst. 2010;102:170–8.CrossRefPubMedGoogle Scholar
  14. 14.
    Welch HG, Schwartz LM, Woloshin S. Ramifications of screening for breast cancer: 1 in 4 cancers detected by mammography are pseudocancers. BMJ. 2006;332:727.CrossRefPubMedPubMedCentralGoogle Scholar
  15. 15.
    Olivotto I, Levine M. Clinical practice guidelines for the care and treatment of breast cancer: the management of ductal carcinoma in situ (summary of the 2001 update). C M A J. 2001;165:912–3.Google Scholar
  16. 16.
    Lari SA, Kuerer HM. Biological markers in DCIS and risk of breast recurrence: a systematic review. J Cancer Educ. 2011;2:232.CrossRefGoogle Scholar
  17. 17.
    Daly MB. Tamoxifen in ductal carcinoma in situ. Semin Oncol. 2006;33:647–9.CrossRefPubMedGoogle Scholar
  18. 18.
    Rakovitch E, Nofech-Mozes S, Hanna W, Narod S, Thiruchelvam D, Saskin R, et al. HER2/neu and Ki-67 expression predict non-invasive recurrence following breast-conserving therapy for ductal carcinoma in situ. Br J Cancer. 2012;106:1160–5.CrossRefPubMedPubMedCentralGoogle Scholar
  19. 19.
    von Minckwitz G, Darb-Esfahani S, Loibl S, Huober J, Tesch H, Solbach C, et al. Responsiveness of adjacent ductal carcinoma in situ and changes in HER2 status after neoadjuvant chemotherapy/trastuzumab treatment in early breast cancer—Results from the GeparQuattro study (GBG 40). Breast Cancer Res Treat. 2012;132:863–70.CrossRefGoogle Scholar
  20. 20.
    Horimoto Y, Tokuda E, Arakawa A, Kosaka T, Saito M, Kasumi F. Significance of HER2 protein examination in ductal carcinoma in situ. J Surg Res. 2011;167:e205–10.CrossRefPubMedGoogle Scholar
  21. 21.
    Roses RE, Paulson EC, Sharma A, Schueller JE, Nisenbaum H, Weinstein S, et al. HER-2/neu overexpression as a predictor for the transition from in situ to invasive breast cancer. Cancer Epidemiol Biomarkers Prev. 2009;18:1386–9.CrossRefPubMedPubMedCentralGoogle Scholar
  22. 22.
    Kurbel S. In search of triple-negative DCIS: tumor-type dependent model of breast cancer progression from DCIS to the invasive cancer. Tumour Biol. 2013;34:1–7.CrossRefPubMedGoogle Scholar
  23. 23.
    Fisher B, Dignam J, Wolmark N, Mamounas E, Costantino J, Poller W, et al. Lumpectomy and radiation therapy for the treatment of intraductal breast cancer: Findings from National Surgical Adjuvant Breast and Bowel Project B-17. J Clin Oncol. 1998;16:441–52.CrossRefPubMedGoogle Scholar
  24. 24.
    Cuzick J, Sestak I, Pinder SE, Ellis IO, Forsyth S, Bundred NJ, et al. Effect of tamoxifen and radiotherapy in women with locally excised ductal carcinoma in situ: long-term results from the UK/ANZ DCIS trial. Lancet Oncol. 2011;12:21–9.CrossRefPubMedGoogle Scholar
  25. 25.
    Lyman GH, Giuliano AE, Somerfield MR, Benson AB, Bodurka DC, Burstein HJ, et al. American Society of Clinical Oncology guideline recommendations for sentinel lymph node biopsy in early-stage breast cancer. J Clin Oncol. 2005;23:7703–20.CrossRefPubMedGoogle Scholar

Copyright information

© International Society of Oncology and BioMarkers (ISOBM) 2015

Authors and Affiliations

  • Li Wang
    • 1
  • Wei Zhang
    • 1
  • Shuhua Lyu
    • 1
    • 2
  • Xia Liu
    • 1
  • Tongxian Zhang
    • 1
  • Shan Liu
    • 1
  • Ying Qin
    • 1
  • Xiaoqi Tian
    • 1
  • Yun Niu
    • 1
  1. 1.Department of Breast Cancer Pathology and Research Laboratory, Key Laboratory of Breast Cancer Prevention and TherapyTianjin Medical University, Ministry of Education. Key Laboratory of Cancer Prevention and Therapy, Tianjin. Tianjin Medical University Cancer Institute and Hospital, National Clinical Research Center of CancerTianjinChina
  2. 2.Department of PathologyNankai University Affiliated HospitalTianjinChina

Personalised recommendations